Clinical Trial News and Research

RSS

Turnstone announces ongoing enrollment of Marabex clinical trial

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.

12 Jul 2015

Starting anti-HIV treatment early improves survival among patients with newly diagnosed TB

Starting anti-HIV treatment within two weeks of the diagnosis of tuberculosis, or TB, improved survival among patients with both infections who had very low immune-cell counts, according to an analysis by researchers at the University of Pittsburgh Graduate School of Health.

10 Jul 2015

Recently-developed drug holds great promise for children with acute lymphoblastic leukaemia

A new Australian study shows that a recently-developed drug, already used safely in adult leukaemia clinical trials, holds great promise for some children with an aggressive form of cancer known as acute lymphoblastic leukaemia (ALL).

10 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

Guselkumab drug more effective than current standard of care for psoriasis

A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition.

9 Jul 2015

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

PwC's Health Research Institute (HRI) reports that market forces are driving new sector collaborations– pairing traditional drug makers with insurers, health systems, patient groups and technology firms – to maximize real-world value and health outcomes.

9 Jul 2015

MGH investigators report that medication could augment benefits of bariatric surgery

New findings about the mechanisms involved - or not involved - in the effects of the most common form of bariatric surgery suggest that combining surgery with a specific type of medication could augment the benefits of the procedure. In a report that has been published online in the journal Endocrinology, Massachusetts General Hospital investigators report that the effects of Roux-en-Y gastric bypass (RYGB) do not utilize neurologic pathways controlled by the serotonin 2C receptor.

9 Jul 2015

Progesterone hormone can benefit breast cancer patients

AROUND half of all breast cancer patients could one day benefit from having the cheap and widely-available female hormone progesterone added to their treatment, according to Cancer Research UK funded research published in Nature today (Thursday).

9 Jul 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announced today that the US Food and Drug Administration has approved Entresto™ tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.

8 Jul 2015

Amedica receives FDA feedback on proposed wear testing femoral head protocols

Amedica Corporation, a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced that responses to the U.S. Food and Drug Administration inquiries regarding the Company’s cervical composite silicon nitride interbody device were submitted to the FDA on June 30, 2015.

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

City of Hope offers islet cell transplant program to cure type 1 diabetes

For patients with severe type 1 diabetes, a strict diet and insulin shots are sometimes not enough to sufficiently control their disease. What they need are insulin-producing cells of their own - currently only available through a still-experimental procedure known as islet cell transplantation.

8 Jul 2015

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the independent Data Safety Monitoring Board recommends the continuation, per protocol, of its phase 2 clinical trial of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.

8 Jul 2015

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.

8 Jul 2015

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin citicoline (Jarrow Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence. The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin citicoline or placebo add-on therapy for 12 weeks.

7 Jul 2015

NCC of South Korea, Velos agree to expand use of Velos eResearch for cancer research

The National Cancer Center of South Korea and Velos, Inc. have entered into a seven year agreement to expand the use of Velos eResearch for cancer research nationally throughout South Korea and internationally in collaboration with other research partners.

7 Jul 2015

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.

7 Jul 2015

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

Investigators have discovered the precise molecular steps that enable immune cells implicated in certain forms of asthma and allergy to develop and survive in the body. The findings from Weill Cornell Medical College reveal a new pathway that scientists could use to develop more effective treatments and therapies for the chronic lung disorder.

7 Jul 2015

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

7 Jul 2015

Clinical Trial News and Research

Turnstone announces ongoing enrollment of Marabex clinical trial

Starting anti-HIV treatment early improves survival among patients with newly diagnosed TB

Recently-developed drug holds great promise for children with acute lymphoblastic leukaemia

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Guselkumab drug more effective than current standard of care for psoriasis

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

MGH investigators report that medication could augment benefits of bariatric surgery

Progesterone hormone can benefit breast cancer patients

New research identifies potential treatment for primary effusion lymphoma

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Amedica receives FDA feedback on proposed wear testing femoral head protocols

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

City of Hope offers islet cell transplant program to cure type 1 diabetes

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

NCC of South Korea, Velos agree to expand use of Velos eResearch for cancer research

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer